Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

FaCT Trial (Facilitated Cascade Testing Trial)

Not Applicable

Recruiting

Conditions: BRCA2 Mutation
BRCA1 Mutation

Interventions: Other: Educational Video
Other: Family Letter (Standard of Care)
Other: Mailed Saliva Kit for Genetic Testing
Other: Telephone Counseling

First Posted Date: 2020-11-03

Last Posted Date: 2024-05-09

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 800

Registration Number: NCT04613440

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Anakinra, COVID-19, Cytokine Storm

Phase 2

Withdrawn

Conditions: Covid19
Cytokine Storm
Mechanical Ventilation Complication

Interventions: Drug: 0.9% Saline
Drug: Anakinra

First Posted Date: 2020-10-27

Last Posted Date: 2022-01-25

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT04603742

Locations: 🇺🇸
Weill Cornell Medcine, New York, New York, United States

Re-treatment 225Ac-J591 for mCRPC

Early Phase 1

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: 225Ac-J591

First Posted Date: 2020-10-06

Last Posted Date: 2023-10-31

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 18

Registration Number: NCT04576871

Locations: 🇺🇸
Brooklyn Methodist Hospital - New York Presbyterian, Brooklyn, New York, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Letrozole 2.5Mg Tab
Radiation: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
Drug: Palbociclib 125mg

First Posted Date: 2020-09-24

Last Posted Date: 2024-03-29

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 102

Registration Number: NCT04563507

Locations: 🇺🇸
Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
New York Presbyterian Hospital - Queens, New York, New York, United States

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

Phase 4

Terminated

Conditions: Prolonged Grief Disorder

Interventions: Drug: Naltrexone HCl 50 MG Oral Tablet
Drug: Placebo

First Posted Date: 2020-09-14

Last Posted Date: 2024-08-28

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 9

Registration Number: NCT04547985

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Phase 2

Recruiting

Conditions: Chronic Fatigue Syndrome
Myalgic Encephalomyelitis

Interventions: Drug: NAC 900mg/day
Drug: NAC 3600mg/day
Drug: NAC 0mg/day (Placebo)

First Posted Date: 2020-09-09

Last Posted Date: 2024-05-17

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 95

Registration Number: NCT04542161

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Trauma-focused Psychodynamic Psychotherapy for LGBT Patients With Post-traumatic Stress Disorder

Not Applicable

Completed

Conditions: Post-traumatic Stress Disorder
Complex Post-Traumatic Stress Disorder

Interventions: Behavioral: Trauma-focused psychodynamic psychotherapy

First Posted Date: 2020-08-31

Last Posted Date: 2021-10-07

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 12

Registration Number: NCT04532996

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant

Phase 4

Active, not recruiting

Conditions: HIV Infections
Renal Transplant Rejection

Interventions: Drug: BIKTARVY 50Mg-200Mg-25Mg Tablet

First Posted Date: 2020-08-28

Last Posted Date: 2024-11-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 20

Registration Number: NCT04530630

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Phase 1

Suspended

Conditions: Prostate Cancer

Interventions: Drug: 225Ac-J591
Diagnostic Test: 68Ga-PSMA-HBED-CC injection

First Posted Date: 2020-08-10

Last Posted Date: 2024-07-31

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 105

Registration Number: NCT04506567

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Brooklyn Methodist Hospital - New York Presbyterian, Brooklyn, New York, United States

Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry

Recruiting

Conditions: Obesity
Gastro Esophageal Reflux
Bariatric Surgery Candidate
Weight Loss

Interventions: Other: Endoscopic Bariatric Therapies

First Posted Date: 2020-07-31

Last Posted Date: 2024-06-28

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 9999

Registration Number: NCT04494048

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy